A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resource-poor setting

J Antimicrob Chemother. 2002 May;49(5):875-8. doi: 10.1093/jac/dkf034.

Abstract

A randomized controlled trial was carried out to assess the effectiveness of azithromycin versus a standard regimen with doxycycline/ciprofloxacin in the treatment of sexually transmitted infections in a resource-poor environment. Infection with Chlamydia trachomatis was cured in 23/24 (95.8%) of women in the azithromycin arm versus 19/21 (90.5%) in the doxycycline arm (P = 0.6), resulting in three treatment failures. Gonorrhoea was cured in 55/56 (98.2%) women, with one treatment failure in a patient with concomitant C. trachomatis infection. These results indicate that a single oral dose of azithromycin may prove to be a more effective and convenient treatment for sexually transmitted infections in women in a resource-poor environment

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use*
  • Azithromycin / adverse effects
  • Azithromycin / economics
  • Azithromycin / therapeutic use*
  • Chlamydia Infections / drug therapy
  • Ciprofloxacin / economics
  • Ciprofloxacin / therapeutic use*
  • Doxycycline / adverse effects
  • Doxycycline / economics
  • Doxycycline / therapeutic use*
  • Female
  • Follow-Up Studies
  • Gonorrhea / drug therapy
  • Health Resources
  • Humans
  • Sexually Transmitted Diseases, Bacterial / drug therapy*
  • Sexually Transmitted Diseases, Bacterial / economics
  • Sexually Transmitted Diseases, Bacterial / microbiology
  • South Africa
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Azithromycin
  • Doxycycline